Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.
Rosenstock J, Frias J, Jastreboff AM et al. · Lancet (London, England) · PMID 37385280
Study summary
Main finding
Several retatrutide groups showed greater HbA1c reductions than placebo, and higher-dose groups showed greater weight reduction. Gastrointestinal adverse events were common.
Phase 2 randomized trial · 281 adults with type 2 diabetes
How the study was set up
A randomized, blinded phase 2 study enrolled 281 adults with type 2 diabetes at 42 US centers and compared retatrutide with placebo and dulaglutide over 36 weeks.
What the researchers measured
The primary outcome was HbA1c change at 24 weeks. Later glucose and weight changes and adverse events were also assessed.
How to read this evidence
The paper includes research in people. Its comparison groups, participant selection, follow-up, and measured outcomes determine how far the findings can be applied. The label alone does not establish efficacy or safety.
Results in context
Glucose and weight outcomes differed by study group, and gastrointestinal events were frequent. The controlled investigational product and selected population define the scope of these results.
What this does not establish
This controlled phase 2 study used an investigational formulation and selected population. It does not establish long-term outcomes or the safety of retail research vials.
Publication & source
Why this paper is included
The compound is a named subject of the publication title.
Publication indexing
Randomized Controlled Trial · Clinical Trial, Phase II · Journal Article · Research Support, Non-U.S. Gov't